8 completed, 2 terminated, 1 active not recruiting. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 6 | Completed 3, Terminated 2, Active not recruiting 1 |
Follow AZD 8931: new trials by email Literature Review of AZD 8931 trials Research Report on AZD 8931
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Trial of Antagonism of HER in GI Cancer AZD8931, Irinotecan, Folinic Acid - Metastatic Colorectal Cancer, Recurrent Colorectal Cancer | Phase 2 | Completed | University College, London | 24 | 2014-05-01 | 2019-08-19 |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients AZD2014, AZD4547, AZD5363 - Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | UNICANCER | 999 | 2014-04-23 | 2024-01-10 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer | Phase 2 | Active not recruiting | UNICANCER | 1460 | 2014-04-07 | 2025-01-15 |
| Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer AZD8931, Placebo, Paclitaxel - Metastatic, Gastric or Gastro-oesophageal Junction, Cancer | Phase 2 | Terminated | AstraZeneca | 39 | 2012-04-01 | 2014-09-12 |
| A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females AZD8931 - Healthy | Phase 1 | Completed | AstraZeneca | 26 | 2011-04-01 | 2011-07-29 |
| Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931 [14C] AZD8931 - Healthy | Phase 1 | Completed | AstraZeneca | 6 | 2011-03-01 | 2014-08-13 |
| Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer AZD8931, anastrozole, Placebo - Neoplasms, Breast Neoplasms | Phase 2 | Terminated | AstraZeneca | 482 | 2010-06-01 | 2014-07-25 |
| Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. AZD8931, Paclitaxel - Neoplasms, Metastatic Cancer | Phase 1 | Completed | AstraZeneca | 17 | 2009-10-01 | 2014-07-10 |
| Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) AZD8931, Paclitaxel, Placebo - Neoplasms, Breast Neoplasms | Phase 1 / Phase 2 | Completed | AstraZeneca | 330 | 2009-06-01 | 2016-01-20 |
| A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets AZD8931 - Healthy | Phase 1 | Completed | AstraZeneca | 24 | 2009-03-01 | 2009-10-23 |
| Study of AZD8931 in Patients With Advanced Solid Malignancies AZD8931 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 41 | 2008-02-01 | 2013-03-12 |
Neoplasms (5) · Breast Neoplasms (4) · Neoplasm Metastasis (4) · Colorectal Neoplasms (1)
AstraZeneca (8) · UNICANCER (2) · University College, London (1)
United Kingdom (6) · France (3) · Japan (3) · Brazil (2) · Canada (2) · Czechia (2) · Germany (2) · Peru (2) · Russia (2) · South Korea (2) · Spain (2) · Taiwan (2) · Belgium (1) · Bulgaria (1) · Finland (1)
Mary Stuart (2) · Daniel Hochhauser, BA, MBBS, MRCP, D.PHIL, FRCP (1) · Darren Wilbraham, MBBS, DCPSA (1) · Dr Darren Wilbraham, DICP, MBBS (1) · Dr Serban Ghiorghiu (1) · Dr Serban Ghiorghiu, MD (1) · Emeline Ramos, MD (1) · Jason Clark, BSc (1) · Mary Stuart, Dr. (1) · Mary Stuart, MD (1) · Professor Jose Baselga (1) · S. Tjulandin (1) · Serban Ghiorghiu (1)
PMID 23589215, PMID 24875132, PMID 25007130, PMID 26410619, PMID 27654971, PMID 32067679, PMID 36352028